News | June 15, 2022
CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Subscribe To Our Newsletter & Stay Updated
